P1A antigen – Other Categories

P1A was the first tumour antigen identified to be recognised by cytotoxic T cells. Tumour antigens are highly expressed on tumour cells however, they are also expressed during early embryogenesis then largely silenced in adulthood thus termed onco-fetal antigens. Targetting tumours expressing these antigens is possible due to their absence in adult tissue (apart from within the testes and placenta). The immune response to the P1A antigen is the major component of the tumour rejection response observed in normal mice. P1A antigen has been tested as a vaccine for tumours to induce P1A-specific CD8+ tumour-infiltrating lymphocytes (TILs). Therefore, the P1A antigen is a useful tool in the search in new cancer immunotherapies using targeted tumour-specific antigens.

 

Technical specification

 KD20 peptide Sequence : H-LPYLGWLVF-NH2
 KD20 peptide MW : 1.105.6 g/mol
 KD20 peptide Purity : > 95%
 KD20 peptide Counter-Ion : TFA Salts
Peptide library synthesis KD20 peptide Delivery format : Lyophilized

Price

 

Product Size Price €
Price $
CRB1000445-0.5 mg 0.5 mg 141 € 113 $
CRB1000445-1 mg 1 mg 193 € 154 $
CRB1000445-
CRB1000445-
CRB1000445-

For Bulk Orders